Indication
Open-label
1 clinical trial
2 products
3 drugs
Clinical trial
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Product
GemcitabineProduct
Nab paclitaxelDrug
S1Drug
mFOLFIRINOXDrug
mFOLFOX6